I-Mab Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (IMAB). Impacted investors are advised to contact the firm now.

The law firm is investigating whether I-Mab and certain of its officers and directors made misrepresentations or failed to disclose material information regarding the Company’s business model, financial condition, and clinical progress between January 2020 and October 16, 2025.

Throughout this period, I-Mab relayed a vision of becoming a fully integrated global biopharmaceutical company, highlighted cash resources, and reported progress across its pipeline, including identifying givastomig as the lead clinical program in early 2025 and providing subsequent quarterly updates.

On October 16, 2025, I-Mab announced a strategic transformation to a hub and spoke platform, the pursuit of a Hong Kong IPO, and a rebrand as NovaBridge Biosciences.

Following this news, the stock declined from $6.56 on October 16, 2025 to $5.77 per share the following day.

If you purchased or acquired I-Mab (Nasdaq: IMAB) securities between January 2020 and October 2025, you may be eligible to seek compensation for losses. Contact Shamis & Gentile, P.A. today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.